Edition:
India

KemPharm Inc (KMPH.OQ)

KMPH.OQ on NASDAQ Stock Exchange Global Market

2.68USD
23 Jan 2019
Change (% chg)

$-0.07 (-2.55%)
Prev Close
$2.75
Open
$2.78
Day's High
$2.78
Day's Low
$2.59
Volume
5,595
Avg. Vol
48,702
52-wk High
$8.35
52-wk Low
$1.72

Latest Key Developments (Source: Significant Developments)

Kempharm Announces FDA Approval Of SNDA For Two Additional Strengths Of Apadaz
Monday, 7 Jan 2019 

Jan 7 (Reuters) - KemPharm Inc ::KEMPHARM ANNOUNCES FDA APPROVAL OF SNDA FOR TWO ADDITIONAL STRENGTHS OF APADAZ® (4.08 MG BENZHYDROCODONE/325 MG APAP AND 8.16 MG BENZHYDROCODONE/325 MG APAP).KEMPHARM INC - FULL PRESCRIBING INFORMATION FOR APADAZ CONTAINS A BOXED WARNING.KEMPHARM INC - APADAZ NOW APPROVED IN THREE DOSAGE STRENGTHS.  Full Article

Kempharm Provides Corporate Update On Partnering Process For ADHD Prodrug Portfolio
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - KemPharm Inc ::KEMPHARM PROVIDES CORPORATE UPDATE ON PARTNERING PROCESS FOR ADHD PRODRUG PORTFOLIO.KEMPHARM INC - "NUMBER OF COMPANIES" HAVE SIGNED CONFIDENTIALITY AGREEMENTS WITH CO AND HAVE BEEN CONDUCTING DUE DILIGENCE.KEMPHARM INC - RECEIVED MULTIPLE EARLY OFFERS AND INDICATIONS OF INTEREST FROM BOTH STRATEGIC AND FINANCIAL PARTNERS.KEMPHARM INC - WILL UNDERTAKE A SECOND ROUND OF DISCUSSIONS OVER COMING WEEKS WITH PARTIES THAT HAVE INDICATED INTEREST IN PARTNERING ADHD ASSETS.  Full Article

KemPharm - Co, TwoXAR entered Into Technology Collaboration
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - KemPharm Inc ::KEMPHARM INC - CO, TWOXARENTERED INTO A TECHNOLOGY COLLABORATION TO DEVELOP PRODRUG-BASED THERAPIES FOR MULTIPLE THERAPEUTIC AREAS AND INDICATIONS.  Full Article

Kempharm Says 8.33 Mln Common Stock Offering Priced At $3 Per Share
Friday, 5 Oct 2018 

Oct 5 (Reuters) - KemPharm Inc ::KEMPHARM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.33 MILLION COMMON SHARES PRICED AT $3.00PER SHARE.  Full Article

Kempharm Announces Proposed Public Offering Of Common Stock
Friday, 5 Oct 2018 

Oct 4 (Reuters) - KemPharm Inc ::KEMPHARM ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.KEMPHARM - INTENDS TO USE NET PROCEEDS OF OFFERING PRIMARILY TO FUND AN NDA SUBMISSION FOR KP415, TO INITIATE A PIVOTAL TRIAL FOR KP484.  Full Article

Kempharm Initiates Pivotal Efficacy Trial Of KP415
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Kempharm Inc ::KEMPHARM INITIATES PIVOTAL EFFICACY TRIAL OF KP415.KEMPHARM INC - ENROLLMENT IN TRIAL IS EXPECTED TO TOTAL APPROXIMATELY 140 PATIENTS ACROSS FIVE CLINICAL SITES IN UNITED STATES.  Full Article

KemPharm says completed meeting with FDA on KP415
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - KemPharm Inc -:KemPharm completes successful end-of-Phase 2 meeting on KP415 with FDA.KemPharm - held meeting to discuss status of proposed clinical, non-clinical,abuse liability studies, among others for submission of NDA for KP415​.KemPharm - ‍meeting with FDA helped confirm remain on schedule in KP415 development program, including work required to complete other standard protocols​.  Full Article

KemPharm posts Q3 loss per share $0.68
Friday, 10 Nov 2017 

Nov 9 (Reuters) - KemPharm Inc :KemPharm reports third quarter 2017 results and provides corporate update.Q3 loss per share $0.68.Q3 earnings per share view $-0.67 -- Thomson Reuters I/B/E/S.  Full Article

KemPharm says KP484 allowed to proceed to clinical studies​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Kempharm Inc :kempharm’s kp484 for the treatment of adhd, an investigational prodrug of methylphenidate, allowed to proceed to clinical studies.Kempharm inc - ‍u.s. Food and drug administration has completed its safety review of investigational new drug application for kp484​.  Full Article